---
title: "\"Performance\" FOUR SEAS MER's interim net profit of HKD 13.08 million fell by 36%, with a dividend of 3 cents"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/267955810.md"
description: "FOUR SEAS MER announced its interim results for the six months ending in September, with revenue of 1.77 billion yuan, an increase of 3.2% year-on-year. It recorded a net profit of 13.08 million yuan, a decline of 36.1%, with earnings per share of 3.4 cents. The interim dividend remains at 3 cents"
datetime: "2025-11-30T08:28:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267955810.md)
  - [en](https://longbridge.com/en/news/267955810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267955810.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/267955810.md) | [English](https://longbridge.com/en/news/267955810.md)


# "Performance" FOUR SEAS MER's interim net profit of HKD 13.08 million fell by 36%, with a dividend of 3 cents

FOUR SEAS MER (00374.HK) announced its interim results for the six months ending in September, with revenue of HKD 1.77 billion, an increase of 3.2% year-on-year. It recorded a net profit of HKD 13.08 million, a decline of 36.1%, with earnings per share of 3.4 cents. The interim dividend remains at 3 cents

### 相關股票

- [FOUR SEAS MER (00374.HK)](https://longbridge.com/zh-HK/quote/00374.HK.md)

## 相關資訊與研究

- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-HK/news/281035263.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-HK/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/zh-HK/news/280899096.md)
- [CSC Financial Sticks to Their Buy Rating for Longfor Group Holdings (LNGPF)](https://longbridge.com/zh-HK/news/280898279.md)